1. Academic Validation
  2. Loss of miR-100 and miR-125b results in cancer stem cell properties through IGF2 upregulation in hepatocellular carcinoma

Loss of miR-100 and miR-125b results in cancer stem cell properties through IGF2 upregulation in hepatocellular carcinoma

  • Sci Rep. 2020 Dec 8;10(1):21412. doi: 10.1038/s41598-020-77960-9.
Hyang Sook Seol 1 Yoshimitsu Akiyama 2 San-Eun Lee 3 Shu Shimada 2 Se Jin Jang 4 5
Affiliations

Affiliations

  • 1 Asan Institute for Life Science, Asan Medical Center, Seoul, 05505, South Korea. [email protected].
  • 2 Department of Molecular Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, 113-8519, Japan.
  • 3 Asan Institute for Life Science, Asan Medical Center, Seoul, 05505, South Korea.
  • 4 Asan Institute for Life Science, Asan Medical Center, Seoul, 05505, South Korea. [email protected].
  • 5 Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, 05505, Seoul, South Korea. [email protected].
Abstract

Stemness factors control MicroRNA expression in Cancer Stem Cells. Downregulation of miR-100 and miR-125b is associated with tumor progression and prognosis of various cancers. Comparing miRNA profiling of patient-derived tumorsphere (TS) and adherent (2D) hepatocellular carcinoma cells, miR-100 and miR-125b are identified to have association with stemness. In TS cells, miR-100 and miR-125b were downregulated comparing to 2D cells. The finding was reproduced in Hep3B cells. Overexpression of stemness factors NANOG, OCT4 and SOX2 by introduction of gene constructs in Hep3B cells suppressed these two miRNA expression levels. Treatment of chromeceptin, an IGF signaling pathway inhibitor, decreased numbers of TS and inhibited the Akt/mTOR pathway. Stable cell line of miR-100 and miR-125b overexpression decreased IGF2 expression and inhibited tumor growth in the xenograft model. In conclusion, miR-100 and miR-125b have tumor suppressor role in hepatocellular carcinoma through inhibiting IGF2 expression and activation of the Akt/mTOR pathway.

Figures
Products